Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03430050 · ClinicalTrials.gov registry record · Early Phase 1
Progesterone for Cannabis Withdrawal
A Early Phase 1 study of Cannabis Use Disorder and Cannabis Withdrawal, sponsored by Medical University of South Carolina.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT03430050: Completed Early Phase 1 study of Cannabis Use Disorder and Cannabis Withdrawal, sponsored by Medical University of South Carolina.
NCT03430050 is a Early Phase 1 study of Cannabis Use Disorder and Cannabis Withdrawal that has completed, run by Medical University of South Carolina. The registered enrollment target is 8 participants, below the 109-participant average among 34 other Cannabis Use Disorder trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03430050, a Early Phase 1 study of Cannabis Use Disorder and Cannabis Withdrawal, has completed, sponsored by Medical University of South Carolina.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
Sex and gender differences in behavioral, biological, and clinical correlates of substance use disorders are myriad, yet there exists a dearth of gender-informed treatment options. Ovarian hormones have been identified as potential mechanisms of these disparities , and recent clinical trials have begun to examine their utility as possible pharmacotherapeutic agents. The ovarian hormone progesterone has shown promise as a treatment for female cocaine and nicotine users, but has not yet been tested for cannabis. Gender differences in cannabis withdrawal, which is associated with relapse, are pronounced and several studies report more severe and impairing withdrawal symptoms in women compared to men. Developing pharmacological interventions for cannabis withdrawal remains an important priority given the significant cognitive, psychiatric, and physical consequences of heavy cannabis use.
Primary Outcome
Participants took progesterone or placebo for 5 days. Salivary progesterone was measured each day. Change score was calculating by subtracting Day 1 progesterone levels from Day 5 progesterone levels.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Progesterone
Study Locations (1)
South Carolina
- Medical University of South Carolina - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2017-10-16 |
| Est. Completion | 2018-04-04 |
| Phase | Early Phase 1 |
What the finished NCT03430050 record still lists
NCT03430050 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 109-participant average among 34 other Cannabis Use Disorder trials with a reported enrollment target (93% lower).
The record links to 2 conditions, with Cannabis Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03430050 reports a single indexed study location in South Carolina.
Frequently Asked Questions
What is clinical trial NCT03430050 about?
NCT03430050 is a clinical study titled "Progesterone for Cannabis Withdrawal". Sex and gender differences in behavioral, biological, and clinical correlates of substance use disorders are myriad, yet there exists a dearth of gender-informed treatment options. Ovarian hormones have been identified as potential mechanisms of these disparities , and recent clinical trials have be...
What is the current status of trial NCT03430050?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 8 participants. The study started on 2017-10-16. Estimated completion is 2018-04-04.
What conditions does trial NCT03430050 study?
This clinical trial studies the following conditions: Cannabis Use Disorder, Cannabis Withdrawal.
What interventions are being tested in trial NCT03430050?
The interventions under investigation include: Placebo (DRUG), Progesterone (DRUG).
Who is sponsoring clinical trial NCT03430050?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03430050 being conducted?
This trial has 1 study location across South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cannabis Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03430050's enrollment target sits among peer trials
8 35th of 34 the lowest of 34 other Cannabis Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cannabis Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
SV2A Density Cannabis Use Disorder
RECRUITING · Early Phase 1
-
Cannabinoids and Biological Reactivity to Stress
RECRUITING · Early Phase 1
-
Integrated Treatment for Enhancing Growth in Recovery During Adolescence
RECRUITING · NA
-
Evaluation of a Brief Computerized and Smart Phone-based Intervention for Stress in Regular Cannabis Users
RECRUITING · NA
-
Longitudinal Outpatient Treatment for Cannabis Use Disorder
RECRUITING · Phase 2
-
Psilocybin-assisted Treatment for Cannabis Use Disorder
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI